Navigating the Evolving Landscape of COVID-19: Strategies to Increase Vaccine Confidence and Improve Vaccination Rates in the United States

Published: May 30, 2024

The COVID-19 pandemic has had a significant impact on every individual in the United States. launch of vaccines is estimated to have averted millions deaths and reduced over 18 million related hospitalizations. In September 2023, updated 2023-2024 vaccine that include monovalent component corresponding omicron variant XBB.1.5 reflecting predominant circulating at time strain selection, was approved recommended for use all people ≥ 6 months age. Despite this recommendation, US uptake COVID season been far from optimal, placing many unnecessary risk severe outcomes. This paper provides an overview current state 2023-2024, barriers uptake. With continued evolution virus, potential more virulent variants lower public acceptance vaccination, contributed low are explored, as well provide solutions improving protection future seasons.

Language: Английский

---

Clinical Impact and Cost-Effectiveness of Updated 2023/24 COVID-19 mRNA Vaccination in High-Risk Populations in the United States

Infectious Diseases and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 15, 2025

In the post-pandemic era, people with underlying medical conditions continue to be at increased risk for severe COVID-19 disease, yet vaccination uptake remains low. This study estimated clinical and economic impact of updated 2023/24 Moderna among high-risk adults versus no Pfizer/BioNTech vaccination. A static Markov model was adapted adults, including immunocompromised (IC), chronic lung disease (CLD), kidney (CKD), cardiovascular (CVD), diabetes mellitus (DM) populations in United States (US). Vaccination vaccine current coverage rates prevent considerable hospitalizations CLD (101,309), DM (97,358), CVD (47,830), IC (14,834), CKD (13,558) also provided net cost-savings US$399 million (M)-2129M (healthcare payer) $457M-2531M (societal perspective), depending on population. The return-on-investment positive across all ($1.10-$2.60 gain every $1 invested). Healthcare savings a relative 10% increase ($439M-$2342M), from meeting US 2030 targets 70% ($1096M-$5707M). Based higher effectiveness observed real-world evidence studies, additional (13,105), (10,359), (6241), (1979), (942) Pfizer/BioNTech's vaccine, healthcare payer societal cost-savings, making it dominant strategy. per patient vaccinated were $31.00-$59.00, Results robust sensitivity/scenario analyses. Updated provide significant health benefits through prevention populations, payers society, Increasing low cost-saving while preventing many more infections these populations. graphical abstract is available this article.

Language: Английский

---

Workplace Vaccination Against COVID-19 and Seasonal Influenza in the United States: A Modeling-Based Estimation of the Health and Economic Benefits for Employers and Employees

Journal of Market Access & Health Policy, Journal Year: 2025, Volume and Issue: 13(2), P. 17 - 17

Published: April 24, 2025

The objectives were to assess the economic burden of COVID-19 and impact workplace vaccination in United States (US). An model estimated (infections, long COVID, inpatient/outpatient care, absent days) with without vaccination, compared seasonal influenza for context, using Optum’s de-identified Clinformatics® Data Mart Database. Without an average US business (with 10,000 employees), had 18,175 days from lost productivity costs USD 5.08 million. Implementing (at 70% coverage) prevented approximately 3132 days, saving employers 876,453 (lost productivity) 240,633 (medical costs); employees 182,196 costs) 198,250 wages) versus no vaccination. greater influenza. Workplace can have a significant both employer through averted disease.

Language: Английский

---

Workplace Vaccination against COVID-19 and Seasonal Influenza in the United States: A Modeling Based Estimation of the Health and Economic Benefits for Employers and Employees

Published: July 24, 2024

Background: COVID-19 has a major impact on businesses, with employee absenteeism resulting in lost productivity and medical costs to employers as well wages employees. The aim of this analysis was assess the economic workplace vaccination United States (US).Methods: A decision tree model, populated US data for working-age population, estimated burden (symptomatic infections, long COVID cases, inpatient/outpatient care, absent days) without vaccination. Disease seasonal influenza studied context. Results: Without vaccination, an average business (with 10,000 employees), had 18,175 days from COVID-19, employer $ 5.08 million. Implementing (at 70% Healthy People target rate) prevented 3,132 days, saving 876,453 $240,633 costs. It also saved employees 182,196 $198,250 . Seasonal caused around 5,333 coverage) 1,675 468,394 27,757 Conclusions: remains businesses. increasing coverage rates potential prevent significant number while providing cost savings averted disease its consequences.

Language: Английский

---

Clinical impact and cost-effectiveness of updated 2023/24 COVID-19 mRNA vaccination in high-risk populations in the United States

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 15, 2024

Abstract Introduction In the post-pandemic era, people with underlying medical conditions continue to be at increased risk for severe COVID-19 disease, yet vaccination uptake remains low. This study estimated clinical and economic impact of updated 2023/24 Moderna among high-risk adults versus no Pfizer/BioNTech vaccination. Methods A static Markov model was adapted adults, including immunocompromised (IC), chronic lung disease (CLD), kidney (CKD), cardiovascular (CVD), diabetes mellitus (DM) populations in United States. Results Vaccination vaccine current coverage rates prevent considerable hospitalizations CLD (101,309), DM (97,358), CVD (47,830), IC (14,834) CKD (13,558) also provided net cost savings $399M–2,129M (healthcare payer) $457M–2,531M (societal perspective), depending on population. The return-on-investment positive across all ($1.10–$2.60 gain every $1 invested). Healthcare a relative 10% increase ($439M–$2,342M), from meeting US 2030 targets 70% ($1,096M–$5,707M). Based higher effectiveness observed real-world evidence studies, additional (13,105), (10,359), (6,241), (1,979), (942) Pfizer/BioNTech’s vaccine, healthcare payer societal savings, making it dominant strategy. per patient vaccinated were $31-59, robust sensitivity/scenario analyses. Conclusions Updated provide significant health benefits through prevention populations, cost-savings payers society, Increasing low cost-saving while preventing many more infections these populations. Key Summary Points Why carry out this study? US, high COVID-19, are CDC recommends an 2024/25 everyone aged >6 months. objective estimate cost-effectiveness conditions, vaccination, What learned mRNA It gains Pfizer/BioNTech, For spent $1.10–$2.60 $31-59 Moderna’s prevented deaths, potential financial greater rates.

Language: Английский

---

Current Status and Significance of Additional Vaccination with COVID-19 Vaccine in Japan—Considerations from Antibody Levels from Hybrid Immunity and Public Perceptions

Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1413 - 1413

Published: Dec. 15, 2024

This report examines the evolving role of coronavirus disease 2019 (COVID-19) vaccination in Japan, especially light reduced public concern following reclassification COVID-19 as a Category 5 infectious May 2023. With over half population estimated to have hybrid immunity from prior infections and vaccinations, this evaluated necessity frequency additional booster doses. Despite strong recommendations Japanese medical societies continue vaccination, skepticism remains owing financial burdens, adverse reactions, perceived limited benefits frequent boosters. Studies on antibody responses revealed that individuals with maintain robust protection significantly elevated titers persist extended periods. Case studies indicated durable among who both been vaccinated experienced breakthrough infections, raising questions about need for uniform policies. also discusses newly approved replicon-type (self-amplifying) vaccines currently available only which generated professional debates regarding their efficacy safety. A more personalized approach takes into account titers, infection history, individual choices is recommended. Finally, underscores importance aligning policies scientific evidence sentiment optimize countermeasures Japan.

Language: Английский

---